tobemstomig PD-1 LAG-3
Selected indexed studies
- Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. (Nat Med, 2025) [PMID:40993242]
- A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma. (Clin Cancer Res, 2026) [PMID:41945490]
- Bilateral Paracentral Corneal Melting and Left-Eye Perforation under Tobemstomig Novel Treatment. (Case Rep Ophthalmol, 2024) [PMID:38299081]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. (2025) pubmed
- A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma. (2026) pubmed
- Bilateral Paracentral Corneal Melting and Left-Eye Perforation under Tobemstomig Novel Treatment. (2024) pubmed